![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 10, 2023
These three trials are open and enrolling adults with multiple myeloma or at high risk of developing the disease
August 17, 2021
This randomized phase III trial aims to determine if the addition of ixazomib to lenalidomide improves overall survival in patients with multiple myeloma
February 25, 2021
The randomized EAA181 phase III trial seeks to determine whether there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients